Brickwork Ratings reaffirms the ratings for the Bank Loan Facilities of Rs. 105.50 Crs. of Godaavari Labs Pvt. Ltd.
Particulars| Facilities** | Amount (Rs.Crs.) | Tenure | Rating# | ||
|---|---|---|---|---|---|
| Previous | Present | Previous (24 Jul 2020) |
Present | ||
| Fund Based | 29.00 | 105.50 | Long Term |
BWR BB-/Stable
Assignment |
BWR BB -
/Stable Reaffirmation |
| Grand Total | 29.00 | 105.50 | (Rupees One Hundred Five Crores and Fifty lakhs Only) | ||
The rating reaffirmation factors in the business and industry experience of the promoters, locational advantage in terms of availability of wide network and channels of distribution in and around Visakhapatnam for API manufacturers, and large base of generic medicine manufacturers in India with consistent demand for APIs. However, the rating is constrained by the overall change in the implementation of the project due to revision in project scope and specifications which has resulted in the extension of the commercial production, time and cost overruns in case of any further delay in the project execution, risks associated with greenfield projects including stabilization and scaling up of operations as per the estimated operating parameters, stringent pricing regulations affecting the profitability of the sector and competition from domestic unorganized players.
The Outlook of the Company continues to remain stable as BWR believes that the Godaavari Labs Private Limited's ('GLPL' or 'the Company') business risk profile will be maintained over the medium term. The outlook may be revised to ‘Positive’ if the company achieves the COD within the stipulated time, ensures stabilization of operations and shows better than expected sales and profitability resulting in an improved financial risk profile. The outlook may be revised to ‘Negative’ in case of any further delay in project execution, cost overrun, and delay in getting regulatory approvals.
BWR has principally relied upon the standalone financials of GLPL up to FY20, provisional financials of FY21, projected financials for FY22 and FY23, and publicly available information and information/clarification as provided by the Company's management.
KEY RATING DRIVERSCredit Strengths:
The company is part of Godaavari Group of Andhra Pradesh. Mr. Sivanageswara Rao Vummaneni and Mrs. Lalitha Kumari Vummaneni are the key promoters of the Company and the Group. They have experience of over two decades in the business of real estate, cotton yarn and mineral water. They hold the positions of directors in the Group companies Sri Lakshmi Godavari Spinning Mills Ltd., Guntur (BWR BB+/Stable/A4+, 09Mar2020), Godavari Townships Private Limited, Visakhapatnam, Vummaneni Townships Private Limited, Visakhapatnam and Vummaneni Mineral Water Products Private Limited, Visakhapatnam. Mr. Sarath Kumar Kumavarapu and Mr. Chandra Mouli Reddy Gogireddy are the other promoters of the Company. They joined the Company in the capacity of technical directors. Mr. Sarath Kumar Kumavarapu has more than two decades of experience in the pharma industry. He also has business interests in various other pharma companies in the capacity of director. Mr. Chandra Mouli Reddy Gogireddy has over three decades of industry experience in managing production operation for finished products with API manufacturing companies.
Visakhapatnam is a manufacturing hub for the APIs and other generic drugs with presence of manufacturing units of big Indian pharmaceutical companies. Jawaharlal Nehru Pharma City is a Pharma SEZ situated in Visakhapatnam. This ensures the presence of the whole network of suppliers, dealers and distributors which can be tapped by the company for both sourcing of raw materials and sale of manufactured APIs.
Despite the economic downturn, the Indian pharmaceutical industry is expected to grow due to consistent demand for generic drugs, both domestically and overseas. Currently, 70% of India's imports of APIs come from China and there was considerable disruption in the imports due to Covid-19 related lockdown and restrictions. To reduce the import dependence, the government’s ‘Make in India’ programme aims to incentivise the production of raw materials, by establishing bulk drug parks and providing other stimulus measures to boost local production of active pharmaceutical ingredients and key starting materials. Also, geopolitical tensions with China may play a role in curtailing import of APIs from China. This will increase the demand of locally produced APIs, which is a positive for the company.
The Company is currently implementing a greenfield project for setting up of API manufacturing unit. The civil work has started in January 2020. However, due to Covid 19 related issues, the progress of the project was disrupted. Further, with change in scope of the project, the overall timeline of the project has extended. Commercial production of the project, which was earlier estimated to be 01 October 2021 is now extended to 01 October 2022. The funding from the bank for additional loan facilities is under process. Various regulatory approvals are in process or yet to be received. There is a possibility of time and cost overrun in case of any further disruption in implementation of the project. Any time or cost overruns could lead to the company facing liquidity pressures. As of 20Sep2021, the company has incurred the project cost of ~Rs. 38.69 Cr against the total planned capital expenditure of Rs. 138.86 Cr. Achievement of COD and stabilization and scaling up of operations as per the project plan are key monitorable.
Indian pharmaceutical companies are subject to multiple regulatory supervisions for different aspects of business. They generally work under supervision of Central Drug Standards and Control Organization (CDSCO) and National Pharmaceutical Pricing Authority (NPPA) in India. They are also subject to the state level pollution control board inspections and certifications. Besides that, the US Food and Drug Administration (US FDA) inspects the manufacturing plants of Indian pharma companies to give approval for export to the US market. The company will have to adhere to the rules and regulations of all these authorities in terms of pricing, quality control, safety and health standards, and several other certifications and control standards.
Indian Pharmaceuticals Industry (IPI) is highly fragmented and competitive in nature with a number of small and medium sized players. Given the proposed scale of operations and the APIs selected for manufacturing, the company will have to compete with both organized players with integrated operations and small players manufacturing or trading in the APIs. The intense competition among the incumbents, threat of substitutes, cheap imports, gradual lowering of entry barriers for the industry and pricing regulations of the government may restrict the pricing power for the company.
For arriving at its ratings, BWR has adopted a standalone approach and applied its rating methodology as detailed in the Rating criteria below (hyperlinks provided at the end of this rationale).
RATING SENSITIVITIES
Positive:
Negative:
LIQUIDITY INDICATORS - Stretched
This is greenfield project under implementation. Total project cost of Rs. 138.86 Cr is to be funded through promoter's contribution of Rs. 53.36 Cr and term loan of Rs. 85.50 Cr. For the phase I, the Company has been sanctioned bank loan facilities of Rs. 29.00 Cr comprising term loan of Rs. 24.00 Cr and cash credit of Rs. 5.00 Cr. Term loan repayment would start from Q1 of FY23 and interest costs on the term is to be serviced as and when charged. The cash credit facility would be availed upon commercialization. The Company is yet to receive the final approval from its bank for proposed additional term loan of Rs. 61.50 Cr and proposed additional cash credit of Rs. 15.00 Cr for phase II of the project. Hence, currently the Company has nil debt servicing obligation. However, as the commercial production is estimated to commence from October 2022, cash flow from operation to ensure liquidity for timely servicing of repayment obligations of the availed term loan is the key monitorable. Timely implementation and stabilisation of the project leading to anticipated revenue, profitability and cash accruals will be crucial for ensuring liquidity.
ABOUT THE ENTITYGodaavari Labs Private Limited (GLPL) was incorporated on 27Feb2013 as a private limited company in Visakhapatnam. Mr. Vummaneni Siva Nageswara Rao, Mrs. Vummaneni Lalitha Kumari, Mr. Chandra Mouli Reddy Gogireddy, Mr. Sarath Kumar Kamavarapu and Mr. Vummaneni Rajesh are the promoter/directors of the Company.
The company proposes to set up a Bulk Drug or Active Pharmaceutical Ingredients (API) and API intermediaries manufacturing unit. The manufacturing unit is being established at Plot No. 22, APSEZ, De-notified Area, Lalamkoduru (V), Rambilli (M), Visakhapatnam, A.P. Total project cost of Rs. 138.86 Crs (Phase I of Rs. 46.99 Cr and Phase II of Rs. 91.87 Cr) is proposed to be funded by promoters' contribution of Rs 53.36 Cr (38.43%) and a Term Loan of Rs. 85.50 Cr (61.57%) from Bank (Union Bank of India).
Project under implementation:
The project for production of Active Pharmaceutical Ingredients (API) and API intermediaries is under implementation. The company has obtained Consent Order for Establishment (CfE) approval for 25 APIs and API intermediaries and has chosen to produce 11 APIs and API intermediaries initially with a total proposed capacity of 2,64,000 kg per annum. The eleven APIs are Omeprazole, Pantoprazole Sodium, Domperidone, Pirfenidone, Chlorthalidone, Mycophenolate mofetil, Tadalafil, Dolutegravir, Darunavir, Quetiapine Fumarate and Fexofenadine Hydrochloride. The land has been purchased and construction work is under process. The commercial production is expected to start in October 2022. As of 20Sep2021, the company has incurred the project cost of ~Rs. 38.69 Cr against the total planned capital expenditure of Rs. 138.86 Cr.
| Standalone Financial Indicators (in ₹ crore) | Units | FY 19-20 (A) | FY 18-19 (A) | |
|---|---|---|---|---|
| Operating Revenue | Rs.Crs. | Not Available | Not Available | |
| EBITDA | Rs.Crs. | -0.01 | -0.01 | |
| PAT | Rs.Crs. | -0.01 | -0.01 | |
| Tangible Net Worth | Rs.Crs. | 2.90 | 2.91 | |
| Total Debt/Tangible Net Worth | Times | 0.89 | 0.10 | |
| Current Ratio | Times | 0.10 | 0.01 | |
|
* A:Audited UA:Unaudited P:Provisional PROJ:Projected
|
||||
|
Note: These are latest available financial results. All ratios as per BWR's calculations; Amount in ₹ crore
|
||||
| Facilities | Current Rating (2021) | 2020 | 2019 | 2018 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Type | Tenure | Amount (Rs.Crs.) |
Rating | Date | Rating | Date | Rating | Date | Rating |
| Fund Based | LT | 105.50 |
BWR BB-/Stable
(Reaffirmation) |
24Jul2020 |
BWR BB-Stable
(Assignment) |
NA |
NA
|
NA |
NA
|
| Grand Total | 105.50 | (Rupees One Hundred Five Crores and Fifty lakhs Only) | |||||||
BWR complexity levels are meant for educating investors. The BWR complexity levels are available at www.brickworkratings.com / download / ComplexityLevels.pdf. Investors queries can be sent to info@brickworkratings.com.
Hyperlink/Reference to applicable Criteria| Analytical Contacts | |
|---|---|
|
Rajaram Gouda Senior Rating Analyst Board : +91 80 4040 9940 rajaram.g@brickworkratings.com |
Hemant Sagare Senior Manager - Ratings Board : +91 80 4040 9940 hemant.s@brickworkratings.com |
| 1-860-425-2742 | media@brickworkratings.com | |
| SL.No. | Name of the Bank/Lender | Type Of Facilities | Long Term(Rs.Crs.) | Short Term(Rs.Crs.) | Total(Rs.Crs.) | |
|---|---|---|---|---|---|---|
| 1 | Union Bank of India | Term LoanProposed | 61.50 | _ | 61.50 | |
| 2 | Union Bank of India | Term LoanSanctioned | 24.00 | _ | 24.00 | |
| 3 | Union Bank of India | Cash CreditProposed | 15.00 | _ | 15.00 | |
| 4 | Union Bank of India | Cash CreditSanctioned | 5.00 | _ | 5.00 | |
| Total | 105.50 | 0.00 | 105.50 | |||
| TOTAL (Rupees One Hundred Five Crores and Fifty lakhs Only) | ||||||
The Rating Rationale is sent to you for the sole purpose of dissemination through your print, digital or electronic media. While it may be used by you acknowledging credit to BWR, please do not change the wordings in the rationale to avoid conveying a meaning different from what was intended by BWR. BWR alone has the sole right of sharing (both direct and indirect) its rationales for consideration or otherwise through any print or electronic or digital media.
About Brickwork RatingsBrickwork Ratings (BWR), a Securities and Exchange Board of India [SEBI] registered Credit Rating Agency and accredited by Reserve Bank of India [RBI], offers credit ratings of Bank Loan, Non- convertible / convertible / partially convertible debentures and other capital market instruments and bonds, Commercial Paper, perpetual bonds, asset-backed and mortgage-backed securities, partial guarantees and other structured / credit enhanced debt instruments, Security Receipts, Securitization Products, Municipal Bonds, etc. BWR has rated over 11,400 medium and large corporates and financial institutions’ instruments. BWR has also rated NGOs, Educational Institutions, Hospitals, Real Estate Developers, Urban Local Bodies and Municipal Corporations. BWR has Canara Bank, a leading public sector bank, as one of the promoters and strategic partner. BWR has its corporate office in Bengaluru and a country-wide presence with its offices in Ahmedabad, Chandigarh, Chennai, Hyderabad, Kolkata, Mumbai and New Delhi along with representatives in 150+ locations.
Disclaimer
Brickwork Ratings India Pvt. Ltd. (BWR), a Securities and Exchange Board of India [SEBI] registered Credit Rating Agency and accredited by the Reserve Bank of India [RBI], offers credit ratings of Bank Loan facilities, Non- convertible / convertible / partially convertible debentures and other capital market instruments and bonds, Commercial Paper, perpetual bonds, asset-backed and mortgage-backed securities, partial guarantees and other structured / credit enhanced debt instruments, Security Receipts, Securitization Products, Municipal Bonds, etc. [ hereafter referred to as "Instruments"]. BWR also rates NGOs, Educational Institutions, Hospitals, Real Estate Developers, Urban Local Bodies and Municipal Corporations.
BWR wishes to inform all persons who may come across Rating Rationales and Rating Reports provided by BWR that the ratings assigned by BWR are based on information obtained from the issuer of the instrument and other reliable sources, which in BWR's best judgment are considered reliable. The Rating Rationale / Rating Report & other rating communications are intended for the jurisdiction of India only. The reports should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in Europe and also the USA).
BWR also wishes to inform that access or use of the said documents does not create a client relationship between the user and BWR.
The ratings assigned by BWR are only an expression of BWR's opinion on the entity / instrument and should not in any manner be construed as being a recommendation to either, purchase, hold or sell the instrument.
BWR also wishes to abundantly clarify that these ratings are not to be considered as an investment advice in any jurisdiction nor are they to be used as a basis for or as an alternative to independent financial advice and judgment obtained from the user's financial advisors. BWR shall not be liable to any losses incurred by the users of these Rating Rationales, Rating Reports or its contents. BWR reserves the right to vary, modify, suspend or withdraw the ratings at any time without assigning reasons for the same.
BWR's ratings reflect BWR's opinion on the day the ratings are published and are not reflective of factual circumstances that may have arisen on a later date. BWR is not obliged to update its opinion based on any public notification, in any form or format although BWR may disseminate its opinion and analysis when deemed fit.
Neither BWR nor its affiliates, third party providers, as well as the directors, officers, shareholders, employees or agents (collectively, "BWR Party") guarantee the accuracy, completeness or adequacy of the Ratings, and no BWR Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Rating Rationales or Rating Reports. Each BWR Party disclaims all express or implied warranties, including, but not limited to, any warranties of merchantability, suitability or fitness for a particular purpose or use. In no event shall any BWR Party be liable to any one for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Rating Rationales and/or Rating Reports even if advised of the possibility of such damages. However, BWR or its associates may have other commercial transactions with the company/entity. BWR and its affiliates do not act as a fiduciary.
BWR keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of BWR may have information that is not available to other BWR business units. BWR has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.
BWR clarifies that it may have been paid a fee by the issuers or underwriters of the instruments, facilities, securities etc., or from obligors. BWR's public ratings and analysis are made available on its web site, www.brickworkratings.com. More detailed information may be provided for a fee. BWR's rating criteria are also generally made available without charge on BWR's website.
This disclaimer forms an integral part of the Ratings Rationales / Rating Reports or other press releases, advisories, communications issued by BWR and circulation of the ratings without this disclaimer is prohibited.
BWR is bound by the Code of Conduct for Credit Rating Agencies issued by the Securities and Exchange Board of India and is governed by the applicable regulations issued by the Securities and Exchange Board of India as amended from time to time.